Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Gross Margin (2016 - 2025)

Historic Gross Margin for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 56.34%.

  • Adma Biologics' Gross Margin rose 65600.0% to 56.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.71%, marking a year-over-year increase of 57800.0%. This contributed to the annual value of 51.48% for FY2024, which is 170400.0% up from last year.
  • Per Adma Biologics' latest filing, its Gross Margin stood at 56.34% for Q3 2025, which was up 65600.0% from 55.11% recorded in Q2 2025.
  • Adma Biologics' Gross Margin's 5-year high stood at 56.34% during Q3 2025, with a 5-year trough of 10.73% in Q1 2021.
  • Moreover, its 5-year median value for Gross Margin was 28.36% (2022), whereas its average is 29.35%.
  • Over the last 5 years, Adma Biologics' Gross Margin had its largest YoY gain of 3269500bps in 2021, and its largest YoY loss of -943500bps in 2021.
  • Over the past 5 years, Adma Biologics' Gross Margin (Quarter) stood at 6.38% in 2021, then surged by 344bps to 28.36% in 2022, then skyrocketed by 48bps to 42.06% in 2023, then rose by 28bps to 53.88% in 2024, then rose by 5bps to 56.34% in 2025.
  • Its Gross Margin was 56.34% in Q3 2025, compared to 55.11% in Q2 2025 and 53.22% in Q1 2025.